Abstract
Purpose: De novo metastatic breast cancer (DMBC) represents approximately 6% of patients with breast cancer [1]. The role of locoregional treatment (LRT) remains controversial, with conflicting trial evidence [2–4]. Palliative systemic therapy remains the mainstay of treatment. We report the impact of different LRTs on breast cancer survival in this heterogeneous disease.
Full Text
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call